These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer. Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270 [TBL] [Abstract][Full Text] [Related]
3. [The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients]. ławicki S; Czygier M; Gacuta-Szumarska E; Knapp P; Szmitkowski M Pol Merkur Lekarski; 2006 Nov; 21(125):465-8. PubMed ID: 17345841 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary. Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350 [TBL] [Abstract][Full Text] [Related]
5. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603 [TBL] [Abstract][Full Text] [Related]
6. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. Ławicki S; Szmitkowski M; Wojtukiewicz M Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152 [TBL] [Abstract][Full Text] [Related]
7. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. Smith HO; Anderson PS; Kuo DY; Goldberg GL; DeVictoria CL; Boocock CA; Jones JG; Runowicz CD; Stanley ER; Pollard JW Clin Cancer Res; 1995 Mar; 1(3):313-25. PubMed ID: 9815987 [TBL] [Abstract][Full Text] [Related]
8. Macrophage colony-stimulating factor as a marker for malignant germ cell tumors of the ovary. Suzuki M; Kobayashi H; Ohwada M; Terao T; Sato I Gynecol Oncol; 1998 Jan; 68(1):35-7. PubMed ID: 9454657 [TBL] [Abstract][Full Text] [Related]
10. [The plasma levels and diagnostic utility of stem cell factor (SCF) and macrophage-colony stimulating factor (M-CSF) in cervical cancer patients]. Lawicki S; Bedkowska E; Gacuta-Szumarska E; Knapp P; Szmitkowski M Pol Merkur Lekarski; 2008 Jul; 25(145):38-42. PubMed ID: 18839612 [TBL] [Abstract][Full Text] [Related]
11. [Selected hematopoietic cytokines in patients with colorectal cancer]. Mroczko B; Ławicki S; Szmitkowski M; Czygier M; Okulczyk B; Piotrowski Z Pol Merkur Lekarski; 2003 Nov; 15(89):416-9. PubMed ID: 14969133 [TBL] [Abstract][Full Text] [Related]
12. [The plasma levels of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in breast cancer patients]. Ławicki S; Czygier M; Omyła J; Bedkowska E; Szmitkowski M Pol Merkur Lekarski; 2007 Oct; 23(136):259-63. PubMed ID: 18293847 [TBL] [Abstract][Full Text] [Related]
14. [Study on serum vascular endothelial growth factor level in ovarian malignant tumors]. Li L; Wang LM; Zhang W; Zhang JQ; Song HL; Yao DS; Tang Y; Chen XQ; Yang ZH Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):72-6. PubMed ID: 12783691 [TBL] [Abstract][Full Text] [Related]
15. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma. Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D J BUON; 2007; 12(1):99-104. PubMed ID: 17436409 [TBL] [Abstract][Full Text] [Related]
16. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors? Ayhan A; Guven S; Guven ES; Kucukali T Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473 [TBL] [Abstract][Full Text] [Related]
17. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403 [TBL] [Abstract][Full Text] [Related]
18. Angiogenin, interleukins, and growth-factor levels in serum of patients with ovarian cancer: correlation with angiogenesis. Chopra V; Dinh TV; Hannigan EV Cancer J Sci Am; 1996; 2(5):279-85. PubMed ID: 9166545 [TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: Long-term prognosis after five years. Mizutani K; Takeuchi S; Ohashi Y; Yakushiji M; Nishimura H; Takahashi T; Maruhashi T; Ueda K; Noda K; Watanabe Y; Kawana T; Terashima Y; Ochiai K; Goto S; Takaku F; Motoyoshi K Oncol Rep; 2003; 10(1):127-31. PubMed ID: 12469157 [TBL] [Abstract][Full Text] [Related]
20. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma]. Sun LX; Wu Y; Han HQ; Wang QH Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]